Citius Oncology amends license agreement with Eisai, defers $8.2M in LYMPHIR payments to 2025

Citius Pharmaceuticals, Inc.

Total obligations owed to Eisai: $8,233,209.77 including $5.9M milestone and $2.33M development/inventory costs.
Payment schedule: $2,535,317.77 by July 15, 2025; four monthly $2.35M payments; final $2,197,892.07 by Dec 15, 2025.
Interest at 2% per annum on delayed amounts from original due dates.
Parties released each other from claims related to late payment of milestone and other costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.